IDH mutation in glioma changes how brain cells talk to tumor cells
Official title: Impact of IDH mutation on the glioma-neuronal microenvironment
Funded at Massachusetts General Hospital · NIH-11449108 · Data updated 2026-11-12
This project looks at how a specific tumor mutation (IDH) changes the nearby brain environment and helps glioma tumors grow.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 15, 2026 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $632,453 |
| NIH project number | 1R01CA307174-01A1 |
| Project ID | NIH-11449108 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be individuals with IDH-mutant glioma or related brain tumor biology; findings may inform future patient-directed trials.
✕Less likely to help
People without IDH-mutant glioma or brain tumor biology may not directly benefit from this basic science study.
What this research studies
If you or a loved one has IDH-mutant glioma, this project explores how the tumor alters nerve cells and their signals in the brain. It uses animal models and CRISPR methods to study the interactions between tumor cells and neurons, aiming to map the pathways that drive growth. The goal is to identify precise molecular mechanisms so future treatments can interrupt these harmful conversations between tumor and brain cells.
Why it matters
Potential benefit: Understanding these interactions could lead to new therapies that slow or stop tumor growth by targeting neighbor cells and signaling paths in the brain.
How similar studies have gone: Previous work shows tumor-secreted metabolites can influence the brain environment and tumor behavior, supporting hopeful translation.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Cahill, Daniel P. — Massachusetts General Hospital
- Study coordinator: Cahill, Daniel P.
Related research
Other NIH-funded projects on the same topics.
-
Next‑gen oncolytic virus therapy for glioblastoma targeting AKT and ERK
A new cancer therapy using an engineered oncolytic virus to fight glioblastoma by blocking AKT/ERK signals and boosting the body’s immune response, with potential to reduce seizures and improve quality of life.
-
Bone marrow immune cells and glioma progression in teens and young adults
A study in adolescents and young adults with brain tumors looks at how immune cells from bone marrow may influence the progression from low-grade to high-grade gliomas.
-
How RNA Splicing Might Shape Glioma Cell States and Therapy Response
A small NIH-funded project will study how alternative RNA splicing influences glioma cell identities and treatment resistance in patient-derived cells.
-
Liquid biopsy for monitoring high-grade glioma using patient-specific DNA junctions
A Mayo Clinic team tests a blood test that looks for unique tumor DNA pieces in glioblastoma patients to monitor disease without frequent scans.
-
Deciphering how a brain cell pH helper influences glioma growth
A study is exploring whether a brain cell pH regulator (Slc4a4) affects the growth and blood vessel changes of malignant glioma to identify new angles for treatment.
-
Predicting how gene therapy spreads in glioblastoma after surgery to improve treatment coverage
This project uses a gene therapy that helps radiation work better against glioblastoma and builds computer models to predict where the therapy reaches after surgical tumor removal.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.